Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01639248
Title Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors CASI Pharmaceuticals, Inc.
Indications

triple-receptor negative breast cancer

Therapies

ENMD-2076

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Colorado Cancer Center Aurora Colorado 80045 United States Details
Inidiana University Melvin and Bren Simon Cancer Center Indianapolis Indiana 46202 United States Details
Cancer Hospital of Chinese Academy of Medical Science Beijing 100021 China Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field